EWTX (Edgewise Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by EWTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | JONATHAN D ROOT | Director | A | — | — |
| 2026-07-02 | Alan J Russell | Chief Scientific Officer | MIXED | — | — |
| 2026-07-01 | Jonathan C Fox | Director | A | — | — |
| 2026-06-17 | Peter A. Thompson | Director | A | — | — |
| 2026-06-17 | Arlene Morris | Director | A | — | — |
| 2026-06-17 | Laura Brege | Director | A | — | — |
| 2026-06-16 | Christopher Nathan Martin | Director | A | — | — |
| 2026-06-16 | Jonathan C Fox | Director | A | — | — |
| 2026-06-16 | Badreddin Edris | Director | A | — | — |
| 2026-05-05 | Joanne M. Donovan | CMO | MIXED | — | — |
| 2026-04-03 | Jonathan C Fox | Director | A | — | — |
| 2026-04-02 | Joanne M. Donovan | CMO | MIXED | — | — |
| 2026-03-30 | Joanne M. Donovan | CMO | Sell | — | — |
| 2026-01-23 | Badreddin Edris | Director | MIXED | — | — |
| 2026-01-05 | Jonathan C Fox | Director | A | — | — |
| 2025-11-24 | Christopher Nathan Martin | Director | A | — | — |
| 2025-11-13 | Alan J Russell | Chief Scientific Officer | MIXED | — | — |
| 2025-11-13 | Jonathan C Fox | Director | Buy | — | — |
| 2025-11-13 | Michael Nofi | Chief Financial Officer | A | — | — |
| 2025-10-02 | Jonathan C Fox | Director | A | — | — |
| 2025-08-28 | Alan J Russell | Chief Scientific Officer | MIXED | — | — |
| 2025-08-14 | Robert Blaustein | Chief Development Officer | A | — | — |
| 2025-08-14 | R Michael Carruthers | Chief Financial Officer | MIXED | — | — |
| 2025-08-14 | Joanne M. Donovan | CMO | MIXED | — | — |
| 2025-08-14 | Alan J Russell | Chief Scientific Officer | MIXED | — | — |
| 2025-08-14 | KEVIN KOCH | President and CEO | MIXED | — | — |
| 2025-08-14 | Behrad Derakhshan | Chief Business Officer | MIXED | — | — |
| 2025-08-14 | JOHN R MOORE | General Counsel | MIXED | — | — |
| 2025-07-02 | Jonathan C Fox | Director | A | — | — |
| 2025-06-18 | Peter A. Thompson | Director | A | — | — |
| 2025-06-18 | Laura Brege | Director | A | — | — |
| 2025-06-18 | Jonathan C Fox | Director | A | — | — |
| 2025-06-18 | Arlene Morris | Director | A | — | — |
| 2025-06-18 | Badreddin Edris | Director | A | — | — |
| 2025-06-18 | JONATHAN D ROOT | Director | A | — | — |
| 2025-05-07 | R Michael Carruthers | Chief Financial Officer | MIXED | — | — |
| 2025-05-07 | Joanne M. Donovan | CMO | MIXED | — | — |
| 2025-05-07 | JOHN R MOORE | General Counsel | MIXED | — | — |
| 2025-05-07 | Alan J Russell | Chief Scientific Officer | MIXED | — | — |
| 2025-05-07 | KEVIN KOCH | President and CEO | MIXED | — | — |
| 2025-05-07 | Behrad Derakhshan | Chief Business Officer | MIXED | — | — |
| 2025-04-04 | Peter A. Thompson | Director | Buy | — | — |
| 2025-04-04 | OrbiMed Genesis GP LLC | Director | Buy | — | — |
| 2025-04-03 | Jonathan C Fox | Director | A | — | — |
| 2025-03-11 | KEVIN KOCH | President and CEO | MIXED | — | — |
| 2025-03-11 | Alan J Russell | Chief Scientific Officer | MIXED | — | — |
| 2025-02-07 | Alan J Russell | Chief Scientific Officer | MIXED | — | — |
| 2025-02-07 | Behrad Derakhshan | Chief Business Officer | MIXED | — | — |
| 2025-02-07 | KEVIN KOCH | President and CEO | MIXED | — | — |
| 2025-01-30 | Joanne M. Donovan | CMO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 14,809,075 | — |
| — | Director | 14,436,497 | — |
| — | Director | 13,497,456 | — |
| — | 10%+ Owner | 6,071,703 | — |
| — | 10%+ Owner | 1,572,960 | — |
| — | 10%+ Owner | 681,812 | — |
| — | Director | 443,792 | — |
| — | Chief Scientific Officer | 94,203 | — |
| — | Chief Financial Officer | 86,162 | — |
| — | President and CEO | 64,997 | — |
| — | Director | 61,209 | — |
| — | Chief Business Officer | 26,136 | — |
| — | Director | 24,833 | — |
| — | Director | 15,625 | — |
| — | General Counsel | 10,214 | — |
| — | Chief Development Officer | 8,445 | — |
| — | CMO | 4,367 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EWTX quote page; the site-wide leaderboard is on the insider transactions hub.